Intrinsa

Intrinsa is a transdermal testosterone patch designed to deliver 300 mcg of testosterone per day. It was developed by Warner Chilcott and Procter & Gamble specifically for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women, particularly those who have undergone bilateral oophorectomy and hysterectomy (surgical menopause) and are receiving concomitant estrogen therapy. The patch works by restoring testosterone levels to a physiological range, thereby targeting androgen receptors in the brain and peripheral tissues to improve sexual desire and reduce associated distress. While it received marketing authorization in the European Union in 2006 for surgically menopausal women, the FDA issued a "not approvable" letter in 2004 due to concerns regarding long-term cardiovascular and breast cancer safety. The product was eventually withdrawn from the European market by the manufacturer in 2012 for commercial reasons.

Brand names

Intrinsa

Other names

Testosterone transdermal systemTestosterone patchTTP